12 results on '"Worawon Chailimpamontree"'
Search Results
2. Estimated dietary sodium intake in Thailand: A nationwide population survey with 24‐hour urine collections
- Author
-
Worawon Chailimpamontree, Surasak Kantachuvesiri, Wichai Aekplakorn, Raweewan Lappichetpaiboon, Nintita Sripaiboonkij Thokanit, Prin Vathesatogkit, Ananthaya Kunjang, Natthida Boonyagarn, Penmat Sukhonthachit, Narinphop Chuaykarn, Patthrapon Sonkhammee, Payong Khunsaard, Phassakon Nuntapanich, Pattaraporn Charoenbut, Comsun Thongchai, Apinya Uttarachai, Wisrut Kwankhoom, Fuangfah Rattanakanahutanon, Krich Ruangchai, Nadchar Yanti, Natnapa Sasang, Sushera Bunluesin, and Renu Garg
- Subjects
24‐hour urinary sodium ,dietary sodium intake ,population survey ,potassium ,Thailand ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Thailand has committed to reducing population sodium intake by 30% by 2025. However, reliable nationally representative data are unavailable for monitoring progress toward the goal. We estimated dietary sodium consumption using 24‐hour urinary analyses in a nationally representative, cross‐sectional population‐based survey. We selected 2388 adults (aged ≥ 18 years) from the North, South, North‐east, Central Regions, and Bangkok, using multi‐stage cluster sampling. Mean sodium excretion was inflated by 10% to adjust for non‐urinary sources. Multivariate logistic regression was performed to assess factors associated with sodium consumption ≥ 2000 mg. Among 1599 (67%) who completed urine collection, mean age was 43 years, 53% were female, and 30% had hypertension. Mean dietary sodium intake (mg/day) was 3636 (±1722), highest in South (4108 ± 1677), and lowest in North‐east (3316 ± 1608). Higher sodium consumption was independently associated with younger age (Adjusted Odds Ratio (AOR) 2.81; 95% Confidence interval (CI): 1.53‐5.17; p = .001); higher education (AOR 1.79; 95% CI: 1.19‐2.67; p = .005), BMI ≥ 25 (AOR 1.55; 95% CI: 1.09‐2.21; p=.016), and hypertension (AOR 1.58; 95% CI: 1.02‐2.44; p = .038). Urine potassium excretion was 1221 mg/day with little variation across Regions. Estimated dietary sodium consumption in Thai adults is nearly twice as high as recommended levels. These data provide a benchmark for future monitoring.
- Published
- 2021
- Full Text
- View/download PDF
3. Prevalence and risk factors of microalbuminuria in Thai nondiabetic hypertensive patients
- Author
-
Pongsathorn Gojaseni, Angkana Phaopha, Worawon Chailimpamontree, and et al
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Pongsathorn Gojaseni1, Angkana Phaopha1, Worawon Chailimpamontree1, Thaweepong Pajareya1, Anutra Chittinandana21Division of Nephrology, Department of Medicine, Bhumibol Adulyadej Hospital, Directorate of Medical Services, Royal Thai Air Force, Bangkok, Thailand; 2Department of Education, Directorate of Medical Services, Royal Thai Air Force, Bangkok, ThailandPurpose: To assess the prevalence and risk factors of microalbuminuria in nondiabetic hypertensive patients in Thailand.Patients and methods: A cross-sectional study was performed during January to December 2007 at outpatients departments of Bhumibol Adulyadej hospital. Nondiabetic hypertensive patients without a history of pre-existing kidney diseases participated in this study. A questionnaire was used for collecting information on demographics, lifestyle, and family history of cardiovascular and kidney disease. Spot morning urine samples were collected for albuminuria estimation. Albuminuria thresholds were evaluated and defined using albumin-creatinine ratio (ACR).Results: A total of 559 hypertensive patients (283 males, 276 females), aged 58.0 ± 11.6 years were enrolled in this study. Microalbuminuria (ACR 17 to 299 mg/g in males and 25 to 299 mg/g in females) was found in 93 cases (16.6%) [15.0%‑18.2%]. The independent determinants of elevated urinary albumin excretion in a multiple logistic regression model were; body mass index ≥30 (odds ratio (OR) = 2.24, 95% confidence intervals (CI): 1.33–3.76) and dihydropyridine calcium channel blockers (DCCB) use (OR = 1.92, 95% CI: 1.22‑3.02).Conclusion: In Thai nondiabetic hypertensive patients, microalbuminuria was not uncommon. Obesity and use of dihydropyridine calcium channel blocker were found to be the important predictors. Prognostic value of the occurrence of microalbuminuria in this population remains to be determined in prospective cohort studies.Keywords: microalbuminuria, hypertension, obesity, calcium channel blocker, metabolic syndrome
- Published
- 2010
4. Estimated dietary sodium intake in Thailand: A nationwide population survey with 24‐hour urine collections
- Author
-
Narinphop Chuaykarn, Wichai Aekplakorn, Raweewan Lappichetpaiboon, Apinya Uttarachai, Phassakon Nuntapanich, Krich Ruangchai, Renu Garg, Surasak Kantachuvesiri, Payong Khunsaard, Ananthaya Kunjang, Pattaraporn Charoenbut, Natnapa Sasang, Patthrapon Sonkhammee, Nadchar Yanti, Natthida Boonyagarn, Penmat Sukhonthachit, Sushera Bunluesin, Prin Vathesatogkit, Nintita Sripaiboonkij Thokanit, Fuangfah Rattanakanahutanon, Comsun Thongchai, Wisrut Kwankhoom, and Worawon Chailimpamontree
- Subjects
Adult ,Endocrinology, Diabetes and Metabolism ,Urinary system ,Sodium ,Population ,chemistry.chemical_element ,030204 cardiovascular system & hematology ,Logistic regression ,dietary sodium intake ,Excretion ,03 medical and health sciences ,0302 clinical medicine ,Internal Medicine ,Humans ,Medicine ,030212 general & internal medicine ,education ,Urine Specimen Collection ,Original Paper ,education.field_of_study ,business.industry ,24‐hour urinary sodium ,potassium ,Dietary sodium intake ,Sodium, Dietary ,Odds ratio ,Thailand ,Original Papers ,population survey ,Confidence interval ,Cross-Sectional Studies ,chemistry ,Hypertension ,Female ,Cardiology and Cardiovascular Medicine ,business ,Demography - Abstract
Thailand has committed to reducing population sodium intake by 30% by 2025. However, reliable nationally representative data are unavailable for monitoring progress toward the goal. We estimated dietary sodium consumption using 24‐hour urinary analyses in a nationally representative, cross‐sectional population‐based survey. We selected 2388 adults (aged ≥ 18 years) from the North, South, North‐east, Central Regions, and Bangkok, using multi‐stage cluster sampling. Mean sodium excretion was inflated by 10% to adjust for non‐urinary sources. Multivariate logistic regression was performed to assess factors associated with sodium consumption ≥ 2000 mg. Among 1599 (67%) who completed urine collection, mean age was 43 years, 53% were female, and 30% had hypertension. Mean dietary sodium intake (mg/day) was 3636 (±1722), highest in South (4108 ± 1677), and lowest in North‐east (3316 ± 1608). Higher sodium consumption was independently associated with younger age (Adjusted Odds Ratio (AOR) 2.81; 95% Confidence interval (CI): 1.53‐5.17; p = .001); higher education (AOR 1.79; 95% CI: 1.19‐2.67; p = .005), BMI ≥ 25 (AOR 1.55; 95% CI: 1.09‐2.21; p=.016), and hypertension (AOR 1.58; 95% CI: 1.02‐2.44; p = .038). Urine potassium excretion was 1221 mg/day with little variation across Regions. Estimated dietary sodium consumption in Thai adults is nearly twice as high as recommended levels. These data provide a benchmark for future monitoring.
- Published
- 2021
5. Closing the gap between evidence and practice in chronic kidney disease
- Author
-
Katrin Uhlig, Neil R. Powe, Yusuke Suzuki, Shakti Basnet, Jonathan C. Craig, Vlado Perkovic, Worawon Chailimpamontree, Tetsuhiro Tanaka, Charlotte Roberts, Mona Alrukhaimi, Gloria Ashuntantang, Bertram L. Kasiske, Meg Jardine, Dwomoa Adu, and Donal O'Donoghue
- Subjects
Nephrology ,medicine.medical_specialty ,Kidney Disease ,review ,Renal and urogenital ,8.1 Organisation and delivery of services ,Type 2 diabetes ,030204 cardiovascular system & hematology ,Cardiovascular ,03 medical and health sciences ,0302 clinical medicine ,Clinical Research ,Internal medicine ,Health care ,medicine ,030212 general & internal medicine ,implementation ,Intensive care medicine ,Glycemic ,treatment gap ,Other Medical and Health Sciences ,Atherosclerotic cardiovascular disease ,business.industry ,Health Services ,medicine.disease ,Good Health and Well Being ,Hypertension ,Generic health relevance ,business ,chronic kidney disease ,Health and social care services research ,Kidney disease - Abstract
There are major gaps between our growing knowledge of effective treatments for chronic kidney disease (CKD), and the delivery of evidence-based therapies to populations around the world. Although there remains a need for new, effective therapies, current evidence suggests that many patients with CKD are yet to fully realize the benefits of blood pressure-lowering drugs (with and without reducing proteinuria with renin-angiotensin system blockade), wider use of statins to reduce atherosclerotic cardiovascular disease events, and better glycemic control in both type 1 and type 2 diabetes. There are many barriers to optimizing evidence-based nephrology care around the world, including access to health care, affordability of treatments, consumer attitudes and circumstances, the dissemination of appropriate knowledge, the availability of expertise and structural impediments in the delivery of health care. Further investment in implementation science that addresses the major barriers to effective care in a cost-effective manner could yield both local and global benefits.
- Published
- 2017
6. Action plan for optimizing the design of clinical trials in chronic kidney disease
- Author
-
Jonathan C. Craig, Worawon Chailimpamontree, Guillermo Garcia-Garcia, Meg Jardine, Katherine R. Tuttle, Vlado Perkovic, Katrin Uhlig, Neesh Pannu, Mohammed Benghanem Gharbi, Andrew S. Levey, Ikechi G. Okpechi, Bénédicte Stengel, and Caroline S. Fox
- Subjects
Nephrology ,medicine.medical_specialty ,business.industry ,Clinical study design ,Alternative medicine ,review ,Disease ,030204 cardiovascular system & hematology ,medicine.disease ,Clinical trial ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Action plan ,medicine ,Physical therapy ,030212 general & internal medicine ,Intensive care medicine ,business ,Kidney disease - Abstract
High-quality clinical trials are the cornerstone of evidence-based prevention and treatment of a disease, but nephrology has a strikingly weak base of such trials. Building the evidence base to improve outcomes for people with a kidney disease, therefore, requires both greater quantity and quality of clinical trials. To address these issues, we propose that we aim to enroll 30% of people with chronic kidney disease in trials by 2030. Goal 1: Strongly encourage and promote the conduct of clinical trials in people with chronic kidney disease to increase the number of clinical trials conducted. Goal 2: Optimize the design of clinical trials in people with chronic kidney disease. Goal 3: Increase the capacity for conducting clinical trials in people with chronic kidney disease.
- Published
- 2017
7. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
- Author
-
Adeera Levin, Marcello Tonelli, Joseph Bonventre, Josef Coresh, Jo-Ann Donner, Agnes B Fogo, Caroline S Fox, Ron T Gansevoort, Hiddo J L Heerspink, Meg Jardine, Bertram Kasiske, Anna Köttgen, Matthias Kretzler, Andrew S Levey, Valerie A Luyckx, Ravindra Mehta, Orson Moe, Gregorio Obrador, Neesh Pannu, Chirag R Parikh, Vlado Perkovic, Carol Pollock, Peter Stenvinkel, Katherine R Tuttle, David C Wheeler, Kai-Uwe Eckardt, Dwomoa Adu, Sanjay Kumar Agarwal, Mona Alrukhaimi, Hans-Joachim Anders, Gloria Ashuntantang, Shakti Basnet, Aminu K. Bello, Worawon Chailimpamontree, Ricardo Correa-Rotter, Jonathan Craig, Walter G. Douthat, Harold I. Feldman, Mohammad Reza Ganji, Guillermo Garcia-Garcia, Mohammed Benghanem Gharbi, David C. Harris, Vivekanand Jha, David W. Johnson, Rumeyza Kazancioglu, Robyn Langham, Zhi-Hong Liu, Ziad A. Massy, Masaomi Nangaku, Robert G. Nelson, Donal O'Donoghue, Ikechi Okpechi, Roberto Pecoits-Filho, Neil R. Powe, Giuseppe Remuzzi, Charlotte Roberts, Jerome Rossert, Laura Sola, Benedicte Stengel, Ernest K. Sumaili M, Yusuke Suzuki, Tetsuhiro Tanaka, Sajja Tatiyanupanwong, Bernadette Thomas, Katrin Uhlig, Robert Walker, Sarah L. White, Andrzej Wiecek, Chih-Wei Yang, and KAZANCIOĞLU, RÜMEYZA
- Subjects
030232 urology & nephrology ,Psychological intervention ,Drug Evaluation, Preclinical ,030204 cardiovascular system & hematology ,urologic and male genital diseases ,OUTCOMES CONTROVERSIES CONFERENCE ,PLACEBO-CONTROLLED TRIAL ,Global Health ,Patient advocacy ,GLOMERULAR-FILTRATION-RATE ,Article ,03 medical and health sciences ,0302 clinical medicine ,Nursing ,Risk Factors ,Drug Discovery ,Global health ,Medicine ,Humans ,Genetic Predisposition to Disease ,Disease management (health) ,GENOME-WIDE ASSOCIATION ,Renal Insufficiency, Chronic ,SUB-SAHARAN AFRICA ,Disease surveillance ,Clinical Trials as Topic ,CLINICAL-PRACTICE GUIDELINE ,business.industry ,Health Priorities ,NEPHROTOXIC MEDICATION EXPOSURE ,STAGE RENAL-DISEASE ,Disease Management ,General Medicine ,Risk factor (computing) ,Acute Kidney Injury ,Congresses as Topic ,medicine.disease ,female genital diseases and pregnancy complications ,3. Good health ,ARISTOLOCHIC ACID NEPHROPATHY ,Action plan ,Practice Guidelines as Topic ,Disease Progression ,business ,BALKAN ENDEMIC NEPHROPATHY ,Kidney disease - Abstract
The global nephrology community recognises the need for a cohesive plan to address the problem of chronic kidney disease (CKD). In July, 2016, the International Society of Nephrology hosted a CKD summit of more than 85 people with diverse expertise and professional backgrounds from around the globe. The purpose was to identify and prioritise key activities for the next 5-10 years in the domains of clinical care, research, and advocacy and to create an action plan and performance framework based on ten themes: strengthen CKD surveillance; tackle major risk factors for CKD; reduce acute kidney injury-a special risk factor for CKD; enhance understanding of the genetic causes of CKD; establish better diagnostic methods in CKD; improve understanding of the natural course of CKD; assess and implement established treatment options in patients with CKD; improve management of symptoms and complications of CKD; develop novel therapeutic interventions to slow CKD progression and reduce CKD complications; and increase the quantity and quality of clinical trials in CKD. Each group produced a prioritised list of goals, activities, and a set of key deliverable objectives for each of the themes. The intended users of this action plan are clinicians, patients, scientists, industry partners, governments, and advocacy organisations. Implementation of this integrated comprehensive plan will benefit people who are at risk for or affected by CKD worldwide.
- Published
- 2016
8. Probability, Predictors, and Prognosis of Posttransplantation Glomerulonephritis
- Author
-
Worawon Chailimpamontree, Svetlana Dmitrienko, David Landsberg, R. Jean Shapiro, Robert Balshaw, Paul Keown, Alexander B. Magil, Guiyun Li, and John S. Gill
- Subjects
Male ,Nephrology ,Canada ,medicine.medical_specialty ,Time Factors ,Population ,Gastroenterology ,Glomerulonephritis ,Postoperative Complications ,Predictive Value of Tests ,Risk Factors ,Internal medicine ,Ethnicity ,medicine ,Humans ,Clinical Epidemiology ,Survivors ,education ,Kidney transplantation ,Survival analysis ,Probability ,Retrospective Studies ,Sex Characteristics ,education.field_of_study ,business.industry ,Incidence (epidemiology) ,General Medicine ,Prognosis ,medicine.disease ,Kidney Transplantation ,Survival Analysis ,Surgery ,Predictive value of tests ,Female ,Kidney Diseases ,Complication ,business ,Immunosuppressive Agents ,Kidney disease - Abstract
Glomerulonephritis (GN) is the leading cause of chronic kidney disease among recipients of renal transplants. Because modern immunosuppressive regimens have reduced the incidence of rejection-related graft loss, the probability and clinical significance of posttransplantation GN (PTGN) requires reevaluation. In this Canadian epidemiologic study, we monitored 2026 sequential renal transplant recipients whose original renal disease resulted from biopsy-proven GN (36%), from presumed GN (7.8%), or from disorders other than GN (56%) for 15 yr without loss to follow-up. Kaplan-Meier estimates of PTGN in the whole population were 5.5% at 5 yr, 10.1% at 10 yr, and 15.7% at 15 yr. PTGN was diagnosed in 24.3% of patients whose original renal disease resulted from biopsy-proven GN, compared with 11.8% of those with presumed GN and 10.5% of those with disorders other than GN. Biopsy-proven GN in the native kidney, male gender, younger age, and nonwhite ethnicity predicted PTGN. Current immunosuppressive regimens did not associate with a reduced frequency of PTGN. Patients who developed PTGN had significantly reduced graft survival (10.2 versus 69.7%; P < 0.0001). In summary, in the Canadian population, PTGN is a common and serious complication that causes accelerated graft failure, despite the use of modern immunosuppressive regimens.
- Published
- 2009
9. A Matched Cohort Pharmacoepidemiological Analysis of Steroid Free Immunosuppression in Renal Transplantation
- Author
-
Robert Balshaw, Guiyun Li, Worawon Chailimpamontree, John S. Gill, Paul Keown, David Landsberg, Katherine A. Barraclough, and R. Jean Shapiro
- Subjects
Adult ,Graft Rejection ,Male ,medicine.medical_specialty ,Renal function ,Gastroenterology ,Cohort Studies ,Adrenal Cortex Hormones ,HLA Antigens ,Internal medicine ,medicine ,Humans ,Longitudinal Studies ,Kidney transplantation ,Transplantation ,business.industry ,Histocompatibility Testing ,Incidence ,Weight change ,Hazard ratio ,Panel reactive antibody ,Middle Aged ,medicine.disease ,Kidney Transplantation ,Survival Analysis ,Surgery ,Cohort ,Female ,Kidney Diseases ,business ,Immunosuppressive Agents ,Cohort study - Abstract
Background. This longitudinal, sequential, matched closed-cohort design pharmacoepidemiological analysis examined the influence of maintenance steroid therapy in 380 first graft recipients after renal transplantation under conditions of normal clinical practice. Methods. Nonexposed (steroid avoidance, n= 190) and exposed (steroid treated, n= 190) cohorts were matched 1:1 for key demographic factors, including donor source (living or deceased), diabetic status, panel reactive antibody level, recipient age (by decade), and sex. Results. Cohorts were comparable for all variables except median human leukocyte antigen mismatch (4 vs. 3, P=0.03), use oftacrolimus (90.0% vs. 59.5%, P≤0.0001), and ofbasiliximab (94.7% vs. 57.4%, P≤0.0001), which were higher in the nonexposed cohort. Estimated glomerular filtration rate (mL/min/1.73 m 2 ) was comparable at 1 year (median: 58.1 vs. 58.3, P=0.92) and 2 years (median: 55.5 vs. 58.0, P=0.97) in nonexposed and in exposed cohorts (P=0.97). There was no difference in Kaplan-Meier estimates of biopsy-proven acute rejection (14.8% vs. 17.0%; hazard ratio: 0.88, P=0.60) or of 2-year death censored graft failure (4.7% vs. 3.2%; P=0.44) between nonexposed or exposed cohorts. Median total cholesterol (4.6 vs. 5.0 mmol/L, P=0.0002), low-density lipoprotein (2.6 vs. 2.8 mmol/L, P=0.005), high-density lipoprotein levels (1.1 vs. 1.3, P=0.0001), and median weight change from baseline (-1.7 vs. +1.0 kg, P=0.001) were significantly lower in the nonexposed cohort. Forty-five patients (29%) in the nonexposed cohort commenced steroid therapy, principally for graft dysfunction or acute rejection. Conclusion. In summary, steroid avoidance did not negatively impact 2-year graft function, biopsy-proven acute rejection rate, or short-term graft survival and offers clinical benefits, which weigh in the decision regarding maintenance therapy.
- Published
- 2009
10. Liver transplantation: current indications and patient selection for adult patients with chronic liver disease
- Author
-
Wichian, Apiratpracha, Worawon, Chailimpamontree, Phongphob, Intraprasong, and Eric M, Yoshida
- Subjects
Adult ,Time Factors ,Liver Diseases ,Patient Selection ,Humans ,Liver Transplantation - Abstract
Liver transplantation is a life saving procedure for patients with a variety of irreversible acute and chronic liver diseases for which no other therapy is available. To date, success of transplantation has been significantly improved with 1-year graft and patient survival rates of approximately 90%. As new information becomes available the indications for individual diseases have been changed somewhat. This review will provide a general basis for patient selection and timing of liver transplantation for adult patients with chronic liver disease.
- Published
- 2008
11. Prevalence of chronic kidney disease in Thai adult population
- Author
-
Anutra, Chittinandana, Worawon, Chailimpamontree, and Preecha, Chaloeiphap
- Subjects
Adult ,Male ,Creatinine ,Chronic Disease ,Prevalence ,Humans ,Female ,Kidney Diseases ,Middle Aged ,Hospitals, Military ,Thailand ,Aged ,Glomerular Filtration Rate - Abstract
Chronic kidney disease (CKD) is a major public health problem worldwide. Until now, no large-scale data about the prevalence of pre-dialysis CKD has been reported in Thailand.The clinical and laboratory data from the ground air force personnel who were routinely checked up during 2002-2003 were collected and descriptively analyzed. The pilots and air crews were excluded. All personnel were working in Bangkok.15,612 RTAF personnel completed the annual check up. Eighty-two percent were male. The average age was 45.7 +/- 8 (19-65) years. According to the classification of stages of CKD by Kidney Disease Outcome Quality Initiative (K/DOQI), the prevalence of CKD is 9.1% by Cockcroft Gault formula and 4.6% by Modification of Diet in Renal Disease. Patients with diabetes mellitus, hypertension, hypercholesterolemia and proteinuria were found in 8.2%, 45.8 %, 28.2 % and 1.8% respectively. CKD patients were older had higher body weight, Body Mass Index (BMI), blood pressure and blood sugar than non CKD personnel.CKD were not uncommon among RTAF personnel. The Cockcroft-Gault and MDRD equations were different in detecting CKD in the present study. The appropriate equation to determine GFR in Thai population should be evaluated. Low sensitivity of dipstick proteinuria may cause the low prevalence of stage 1 and 2 CKD.
- Published
- 2006
12. GLOMERULONEPHRITIS FOLLOWING RENAL TRANSPLANTATION
- Author
-
R J. Shapiro, David Landsberg, Jagbir Gill, Paul Keown, Alex B. Magil, Worawon Chailimpamontree, Guiyun Li, Robert Balshaw, and Svetlana Dmitrienko
- Subjects
Transplantation ,medicine.medical_specialty ,business.industry ,Urology ,Medicine ,Glomerulonephritis ,business ,medicine.disease - Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.